Massive Intra‐Abdominal Pseudotumor in a Patient With Hemophilia A Treated With Emicizumab: A Case Report

Carolina Digital Repository (University of North Carolina at Chapel Hill) 2026 Open access

Read full text
Authors: C. M. Wanjiku, K. F. Molitor, J. Sagar, F. Njuguna, I. A. Janson, C. Njuguna, C. J. Kilach, S. M. Mbunya, A. D. Shapiro, A. Greist
DOI: 10.17615/gevz-7e29
Cited by: 0

Abstract

Hemophilic pseudotumors, a rare complication of bleeding disorders, are more common in settings with limited access to clotting factor concentrates. Subcutaneous emicizumab, a relatively novel therapy for hemophilia A, was investigated for its ability to stabilize an inoperable pseudotumor in a patient with factor VIII deficiency in an under‐resourced setting.

Fields of Study & Subjects

Hemophilia Treatment and Research Platelet Disorders and Treatments Coagulation Bradykinin Polyphosphates and Angioedema

Publication details

Journal / source
Carolina Digital Repository (University of North Carolina at Chapel Hill)
Publication date
9 January 2026